How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism

The exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, a...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2023-07, Vol.16 (7), p.1011
Main Authors: Janíčková, Mária, Bolek, Tomáš, Stančiaková, Lucia, Nagy, Norbert, Mokáň, Marián, Samoš, Matej
Format: Article
Language:English
Subjects:
Anticoagulants
Blood clots
Blood platelets
Cancer therapies
cancer-associated venous thromboembolism
Care and treatment
Catheters
Clinical medicine
Clinical practice guidelines
Complications and side effects
Diagnosis
direct oral anticoagulants
Head and neck cancer
Hemorrhage
Leukocytes
Neutrophils
oral and facial cancer
Oral cancer
Pancreatic cancer
parenteral anticoagulation
Patients
Pulmonary embolisms
Review
Risk factors
Thromboembolism
Thrombosis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, and consecutively increase CA-VTE-related morbidity and mortality. In addition, there might be specific clinical problems in the treatment of CA-VTE in patients with oral and facial cancer, such as swallowing difficulties, that might limit the possibilities of oral anticoagulation. Finally, there are limited data regarding the optimal treatment of CA-VTE in patients with oral and facial cancer, and this includes data on novel therapeutic strategies, including the use of direct oral anticoagulants. This article reviews current data on the optimal treatment strategy for CA-VTE in patients with OFC.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph16071011